Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
3期
提前终止
NCT04251533
| 适应症 | Triple Negative Breast Neoplasms |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Novartis Pharmaceuticals |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 137 人 |
|---|
| 干预（药物） | alpelisib, nab-paclitaxel |
|---|
| 开始日期 | 2020年6月8日 |
|---|
| 完成日期 | 2023年5月31日 |
|---|
| 结果公布日 | 2024年7月31日 |
|---|
摘要
The purpose of this study was to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1) or PTEN loss without PIK3CA mutation (Study Part B2)
Progression-free Survival (PFS) Per Investigator Assessment in Study Part A
Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months · months
| Part A: Alpelisib + Nab-paclitaxel | 7.2 months |
|---|
| Part A: Placebo + Nab-paclitaxel | 5.6 months |
|---|
| Hazard Ratio (HR) | 1.49 (95% CI 0.92–2.41) |
|---|
Overall Response Rate (ORR) Based on Local Radiology Assessments in Participants With Measurable Disease at Baseline in Study Part B1
Up to 6 months · percentage of participants
| Part B1: Alpelisib + Nab-paclitaxel | 14.3 percentage of participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。